Understanding ALK+ NSCLC: Causes, Prevalence, and Prognosis | Takeda Oncology
Disease Education
Outsmarting Cancer to Profoundly Impact Patients’ Lives
At Takeda Oncology, we aspire to cure cancer with inspiration from patients and innovation from everywhere. We combine rigorous science, innovative commercial operations and the aspiration of transforming cancer from a serious disease to a treatable illness in our efforts to develop transformative medicines. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide.
Cancer is clever, but we know its weaknesses. We’ve discovered new ways to attack vulnerabilities in cancer that affect specific patient populations with significant unmet need.
Patients with limited or ineffective treatment options motivate us every day. We are committed to outsmarting cancer so that more patients can benefit from – and have access to – life-transforming medicines.
Colorectal Cancer
Colorectal cancer (CRC) is cancer of the large intestine, which is made up of the colon and rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start.1 CRC is the third most common cancer worldwide. In 2020, CRC represented about 1 in 10 cancer cases and deaths.2 By 2030, CRC is expected increase by 60%, to over 2.2 million new cases and 1.1 million deaths globally.3
Metastatic Colorectal cancer can also be referred to as advanced colon cancer or stage 4 colon cancer.4
Lung Cancer
Lung cancer is one of the most common cancers and is the leading cause of cancer death worldwide. Even with substantial improvement in cancer screening, diagnosis, and treatment over the past few decades, lung cancer remains the leading cause of cancer death, with approximately 18% of cancer-related deaths worldwide. 1 Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all forms of lung cancer. 2
Takeda Oncology’s advanced lung cancer research is focused on expanding treatment options for people with anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC (mNSCLC). Our ongoing investigation of targeted therapies demonstrates continued progress toward extending and improving the lives of people living with rare forms of NSCLC.
Anaplastic lymphoma kinase-positive (ALK+) NSCLC is a unique type of NSCLC caused by a change in the anaplastic lymphoma kinase (ALK) gene.
Blood Cancer
Hematologic malignancies, or blood cancers, include leukemia, lymphoma, myeloma and myelodysplastic syndromes (MDS). These types of blood cancers can affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system. Each year, more than 1.3 million people worldwide are diagnosed with a blood cancer.
Lymphoma is the most common type of blood cancer and originates from abnormal lymphocytes, a key component of the human immune system. 3
Multiple myeloma is a rare blood cancer that arises from the plasma cells, a type of white blood cell which is made in the bone marrow.
Leukemia is a blood cancer that develops in early blood-forming cells. There are four main types of Leukemia.